Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 14/20 | 0.61 |
| ▸ | AURKA | O14965 | 2/20 | 0.61 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.51 |
| ▸ | GSK3B | P49841 | 3/20 | 0.51 |
| ▸ | SCD | O00767 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.45 |
| ▸ | PRKACG | P22612 | 1/20 | 0.45 |
| ▸ | PRKACB | P22694 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14712491 | 0.95 | ITK (0.60) | ITKAURKADYRK1AGSK3BSCD | |
| SCHEMBL14712604 | 0.94 | ITK (0.66) | ITKAURKADYRK1AGSK3BPRKACA | |
| SCHEMBL14712494 | 0.93 | ITK (0.64) | ITKAURKADYRK1AGSK3BPRKACA | |
| SCHEMBL14712421 | 0.92 | ITK (0.63) | ITKAURKADYRK1AGSK3BPRKACA | |
| SCHEMBL14712405 | 0.91 | ITK (0.58) | ITKAURKADYRK1AGSK3BSCD | |
| SCHEMBL14712415 | 0.90 | ITK (0.61) | ITKAURKADYRK1AGSK3B | |
| SCHEMBL14712416 | 0.89 | ITK (0.64) | ITKAURKADYRK1AGSK3BPRKACA | |
| SCHEMBL14712598 | 0.87 | ITK (0.60) | ITKAURKADYRK1AGSK3BPRKACA | |
| SCHEMBL14712412 | 0.87 | ITK (0.60) | ITKAURKADYRK1AGSK3BPRKACA | |
| SCHEMBL14712596 | 0.87 | ITK (0.59) | ITKAURKADYRK1AGSK3BSCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2742040-B1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2016-04-06 | — | — | EP | disclosed |
| EP-2742040-B1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2016-04-06 | — | — | EP | disclosed |
| US-20140309210-A1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309210-A1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-10-16 | — | — | US | disclosed |
| WO-2013024011-A1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309210-A1 | INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CYP3A43, INSR, CYP2C19 | ITK 1578/4885AURKA 2633/4885DYRK1A 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.